Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences to present at 9th Annual Neurosciences Innovation Forum
03:15am, Friday, 09'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO, Ivor Elrifi, will present at the 9th Annual Neuroscience Innovation Forum on January 11 during J.P....
Oil market surplus predicted to widen through early 2026
07:38am, Monday, 05'th Jan 2026
The oil market surplus that arrived in the second half of 2025 is predicted, by analysts at Morgan Stanley, to widen in early 2026, pushing the Brent...
Saks Global CEO Marc Metrick steps down as retailer reportedly nears bankruptcy
07:08am, Friday, 02'nd Jan 2026
Saks Global CEO Marc Metrick, a 30-year veteran of the luxury retailer, has stepped down to pursue “new opportunities,” the company announced Friday....
Nasdaq, S&P 500 move lower as 2026 trading gets underway
07:04am, Friday, 02'nd Jan 2026
12:04pm: Wall Street wobbles US stocks edged lower in the early afternoon on Friday, led by a 0.4% drop in the Nasdaq. The S&P 500 was down 0.2% and the Dow...
Nasdaq ends Monday in the red in subdued post-holiday session
11:22am, Monday, 29'th Dec 2025
4:20pm: Wall Street cools after holiday rally Stocks closed in the red on Monday, taking a small step back after wrapping up a shortened Christmas trading...
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA
09:11am, Monday, 29'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has submitted its seventh annual Development Safety Update Report (DSUR) to the US Food and Drug Administration (FDA), reporting no drug-rela
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
08:00am, Monday, 29'th Dec 2025
BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer's trial - ICYMI
11:09am, Saturday, 20'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about a series of important developments for the company, including the dosing of its first patient in an early Alzheimer
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer’s trial - ICYMI
06:00am, Saturday, 20'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about a series of important developments for the company, including the dosing...
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
11:00am, Friday, 19'th Dec 2025
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences executive chairman increases stake
06:29am, Friday, 19'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA), a biotechnology firm developing immunomodulation therapies, including intranasal foralumab, said its executive...
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
10:00am, Wednesday, 17'th Dec 2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences doses first patient in mid-stage Alzheimer's trial
09:08am, Wednesday, 17'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Wednesday it has dosed the first patient in a Phase 2 clinical trial testing its intranasal drug candidate foralumab in patients with early Alzheimer's
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial
08:45am, Wednesday, 17'th Dec 2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
03:07pm, Monday, 15'th Dec 2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
